Exchange: NYSE·Updated 10:09 AM EST

HAE News

News
all
press releases
GEHC vs. HAE: Which Stock Is the Better Value Option?
GEHC vs. HAE: Which Stock Is the Better Value Option?
Zacks
GEHC vs. HAE: Which Stock Is the Better Value Option?
GEHC vs. HAE: Which Stock Is the Better Value Option?
Zacks
More News
All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line
Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day LinePR NewswireVANCOUVER, BC, Oct. 19, 2026 VANCOUVER, BC, Oct. 19, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Big tech drove a sharp...
PR Newswire
Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure System
Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure System Haemonetics Announces FDA Approval of PerQseal Elite Vascular Closure SystemPR NewswireBOSTON, Oct. 19, 2026 BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company...
PR Newswire
Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
Zacks
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
Zacks
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff – What’s Driving The Momentum Today?
Pacira BioSciences secured a $1.65 billion buyout deal with Viatris, while Haemonetics expanded its CSL Plasma partnership, prompting BTIG to raise its price target.
Stocktwits
Haemonetics Stock Hits 52-Week High - Here's Why
Haemonetics stock hits a new 52-week high after CSL Plasma outlines a sweeping rollout of its technology across existing U.S. centers.read more...
Benzinga

Advertisement|Remove ads.